The cell therapy proved superior to standard-of-care regardless of cytogenetic risk or prior therapy in the CARTITUDE-4 study ...

Quadruplet therapy is now the accepted standard for patients newly diagnosed with myeloma who are ineligible for transplant; ...

The ASCENT-04/KEYNOTE-D19 study is a global, open-label, randomized phase III study evaluating the efficacy and safety of ...

If the money lapses this year, 5 million are expected to lose coverage and others would face premium hikes in 2026.